Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs

Current Medical Research and Opinion

Volumn 26, Issue 2, 2010, Pages 455-463

  Devine, Scott T ^a   Weisbart, Edmond ^a   Barron, John ^b   Behm, Andrew ^a  

^a Express Scripts   (United States)

^b HEALTHCORE INC   (United States)

Author keywords

Anticonvulsants; Clinical equivalency; Epilepsy; Generic equivalency; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; ETHOTOIN; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; MESUXIMIDE; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ACUTE DISEASE; ADULT; ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; EPILEPSY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CASE-CONTROL STUDIES; CHEMISTRY, PHARMACEUTICAL; COMORBIDITY; DISEASE PROGRESSION; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 74549172142     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903488704     Document Type: Article

References (28)

1. Food and Drug Administration. Therapeutic equivalence of generic drugs. Response to the National Association of Boards of Pharmacy. 1997 [cited 2009 May 26]; Available from: www.fda.gov/cder/news/ntiletter.htm
2. Burkhardt RT, Leppik IE, Blesi K, et al. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 2004;63:1494-1496
3. Duh MS, Paradis PE, Latremouille-Viau D, et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 2009;72:2122-2129
4. Rascati KL, Richards KM, Johnsrud MT, et al. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy 2009;29:769-774
5. Zachry 3rd WM, Doan QD, Clewell JD, et al. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009;50:493-500
6. Berg MJ, Gross RA, Tomaszewski KJ, et al. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008; 71:525-530
7. Gilman JT, Alvarez LA, Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology 1993;43:2696-2697
8. Koch G, Allen JP. Untoward effects of generic carbamazepine therapy. Arch Neurol 1987;44:578-579
9. MacDonald JT. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology 1987;37:1885
10. Welty TE, Pickering PR, Hale BC, et al. Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacother 1992;26:775-777
11. Wyllie E, Pippenger CE, Rothner AD. Increased seizure frequency with generic primidone. JAMA 1987;258:1216-1217
12. Tyrer JH, Eadie MJ, Sutherland JM, et al. Outbreak of anticonvulsant intoxication in an Australian city. Br Med J 1970;4:271-273
13. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2008
14. Andermann F, Duh MS, Gosselin A, et al. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007;48:464-469
15. LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008; 70:2179-2186
16. Gomez-Alonso J, Kanner AM, Herranz JL, et al. Risks and benefits of generic antiepileptic drugs. Neurologist 2008;14(6 Suppl):S66-72
17. Kosanke J, Bergstralh EJ. gmatch SAS Macro. [SAS Macro] 2003 4/7/2004 [cited 2009 June 29]; Match 1 or more controls to cases using the GREEDY algorithm]. Available from: http://mayoresearch.mayo.edu/mayo/research/ biostat/upload/gmatch.sas
18. Medi-Span Master Drug Database v2.5. Indianapolis, IN: Wolters Kluwer Health, Inc., 2009
19. Hernan MA, Hernandez-Diaz S, Werler MM, et al. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol 2002;155:176-184
20. Rosenow F, Hamer HM, Knake S. The epidemiology of convulsive and non-convulsive status epilepticus. Epilepsia 2007;48(Suppl 8):82-84
21. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-1251
22. Chadwick D. Monotherapy clinical trials of new antiepileptic drugs: design, indications, and controversies. Epilepsia 1997;38(Suppl 9):S16-20
23. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2:347-356 (Pubitemid 38352562)
24. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007;147:W163-94
25. Wacholder S, McLaughlin JK, Silverman DT, et al. Selection of controls in case-control studies. I. Principles. Am J Epidemiol 1992;135:1019-1028
26. Poole C. Exposure opportunity in case-control studies. Am J Epidemiol 1986; 123:352-358
27. Patsalos PN, Froscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43:365-385
28. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-481 (Pubitemid 36876104)